Last reviewed · How we verify
NCT07416513: ALTHEA
Digital Solutions for bEtter cAre
NA trial testing Patients, survivors, caregivers, family members and healthcare professionals in Cancer Diagnosis in 200 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 200 |
| Start date | 14 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 5 locations across France, Italy, Germany, Lithuania, Spain |
Drugs / interventions tested
- Patients, survivors, caregivers, family members and healthcare professionals
Conditions studied
- Cancer Diagnosis — all drugs for Cancer Diagnosis →
Sponsor
European Institute of Oncology
Who can join
12 and older, any sex, with Cancer Diagnosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The target population includes cancer patients, caregivers, family members, healthcare providers and mental health specialists, who will be the primary end-users of the Althea platform. For patients, survivors, caregivers, and family members, the sample variables include age, gender, type and stage of disease, and time since the first diagnosis. The healthcare professionals that will be involved in this study are those who attend to oncological patients, with sample variables such as age, gender, professional role, and prior experience and training in oncology or psycho-oncology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07416513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer Diagnosis
Currently open trials in the same condition.
- NCT06523868 — Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study · NA · recruiting
- NCT06645691 — Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body · Phase 2 · recruiting
- NCT06502483 — PRISM for Depression and Anxiety in Young Adults With Cancer · NA · active not recruiting
- NCT06822413 — Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis · recruiting
- NCT05142033 — Avera Cancer Sequencing and Analytics Protocol (ASAP) · recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07416513 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07416513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing